For over a decade thiazolidinediones (TZDs) have been used for glycemic control for diabetic patients. During that time studies and clinical findings demonstrated that TZDs resulted in adverse cardiovascular events. Now additional studies point to increased risks of stroke, AMI (acute myocardial infarct), heart failure and death.
It is hoped that in light of these findings the FDA will reconsider the continued marketing of rosiglitazone.
Rosiglitazone: More Evidence Showing Adverse Cardiovascular Events (7.2.10)
July 2, 2010
great information you write it very clean. I am very lucky to get this tips from you.
Thanks for this
information